Dartmouth biotech company IMV on Tuesday revealed “breakthrough” results in the Phase 2 clinical trials of its flagship drug DPX-Survivac, which sparked a sell-off of its shares that was as puzzling as it was dramatic.
IMV, which specializes in using a person’s immune system to battle such diseases as cancer, announced an update on DPX-Survivac, saying the study of 22 patients with advanced recurrent ovarian cancer marked a “pivotal milestone” for the company.
The study was able to draw data from 19 patients, and 15 of them, or 79 percent, “achieved disease control". Also, 10 of them, or 53